Breaking news: NHMRC backs puberty blockers for young patients with gender incongruence
The NHMRC has backed the current clinical use of puberty blockers for those under 18 with gender incongruence, not just those diagnosed with gender dysphoria.
Its interim advice, published today, says that puberty suppressants — specifically, gonadotropin-releasing hormone agonists (GnRH agonists) — can be considered as a treatment option by clinicians.
“The use of puberty suppressants is one possible part of care, not the entirety of care. It is not necessary to wait until a young person is distressed before providing care,” it says.
It comes more than 18 months after the Queensland Government banned the initiation of the drugs in those under 16 in its public clinics, saying there was insufficient evidence of their safety or efficacy.